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Introduction
Recent evidence is emerging that ER stress contributes to the pathogenesis of  vascular calcification (1–10). 
The ER is a major site for the regulation of  calcium and lipid homeostasis (11). ER stress is an integrated 
signal transduction pathway involved in the localization and folding of  secreted and transmembrane pro-
teins. A number of  cellular stress conditions, including lipid accumulation, lead to the accumulation of  
unfolded proteins in the ER lumen. The three ER resident sensors, PKR-like endoplasmic reticulum kinase 
(PERK), inositol-requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) implement the 
ER stress response (12). Among the three pathways of  the ER stress response, our previous studies strongly 
implicate the PERK-initiated pathway in the development of  vascular calcification (7–10). Activation of  
PERK leads to the phosphorylation of  the α-subunit of  eukaryotic initiation factor 2 (eIF2α), which inhib-
its assembly of  the 80S ribosome and protein synthesis. However, ATF4 is not affected by the translational 
attenuation of  eIF2α phosphorylation due to the existence of  several small upstream open reading frames 
in its 5′-untranslated regions. These upstream open reading frames, which prevent translation of  ATF4 
under normal conditions, are bypassed only when eIF2α is phosphorylated, thereby permitting translation 
(13–15). ATF4 is a pivotal transcription factor that mediates not only ER stress, but also osteoblastic dif-
ferentiation (16–19). In the late stage of  osteoblastic differentiation, ATF4 directly induces osteocalcin, an 
osteoblast-specific marker, and osterix, another essential transcription factor, through their osteo-specific 
elements (OSE) (17, 19). ATF4 is also required for preserving mature osteoblast functions, including the 
synthesis of  collagen, the most abundant extracellular protein found in bones and calcified vasculatures 
(19). PERK/eIF2α/ATF4 pathway–mediated ER stress is involved in osteoblast differentiation induced by 
bone morphogenetic protein-2 and other factors (8, 20). In addition, we and other groups recently reported 
ectopic ATF4 expression in rodent models of  vascular calcification (1, 2, 5, 7, 8, 10). However, the in vivo 
role of  ATF4 in the regulation of  vascular calcification and vascular osteogenesis has yet to be determined.
Emerging evidence indicates that upregulation of the ER stress–induced pro-osteogenic 
transcription factor ATF4 plays an important role in vascular calcification, a common complication 
in patients with aging, diabetes, and chronic kidney disease (CKD). In this study, we demonstrated 
the pathophysiological role of ATF4 in vascular calcification using global Atf4 KO, smooth muscle 
cell–specific (SMC-specific) Atf4 KO, and transgenic (TG) mouse models. Reduced expression 
of ATF4 in global ATF4-haplodeficient and SMC-specific Atf4 KO mice reduced medial and 
atherosclerotic calcification under normal kidney and CKD conditions. In contrast, increased 
expression of ATF4 in SMC-specific Atf4 TG mice caused severe medial and atherosclerotic 
calcification. We further demonstrated that ATF4 transcriptionally upregulates the expression of 
type III sodium-dependent phosphate cotransporters (PiT1 and PiT2) by interacting with C/EBPβ. 
These results demonstrate that the ER stress effector ATF4 plays a critical role in the pathogenesis 
of vascular calcification through increased phosphate uptake in vascular SMCs.
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Vascular calcification is an independent predictor for the mortality and morbidity of  patients with 
chronic kidney disease (CKD) (4, 21). Vascular calcification is classified into two major types, atheroscle-
rotic and medial, both of  which are frequently and simultaneously observed in CKD patients. Vascular 
calcification is a highly regulated process that resembles skeletal bone formation. Many key transcriptional 
regulators involved in skeletal osteogenesis, such as Msx-2, osterix, and Runx-2, are expressed in both 
calcified medial arterial layers and atherosclerotic plaques (22, 23). In addition, many causative hormonal 
factors (TNF-α, FGF23/Klotho, and phosphorus) and lipid-derived factors (saturated fats and oxidized 
lipids) have been identified in vascular calcification (7–10, 24–29). We recently reported that these factors 
induce ATF4 activation through the ER stress response, resulting in osteogenic differentiation and mineral-
ization of  vascular smooth muscle cells (VSMCs) in vitro (8, 9). However, whether in vivo ATF4 activation 
causes ectopic vascular osteogenesis and the molecular mechanism by which ATF4 induces mineralization 
of  VSMCs have not been determined. In this context, we determined the in vivo role of  ATF4 in VSMCs 
in both atherosclerotic and medial calcification and its mechanisms by using several murine models with 
global ATF4 deficiency, smooth muscle cell–specific (SMC-specific) ATF4 deficiency, and SMC-specific 
ATF4 overexpression.
Results
Global ATF4 haplodeficiency attenuates medial calcification. The in vivo role of  ATF4 in the regulation of  vas-
cular calcification and vascular osteogenesis has yet to be determined. Medial calcification is characterized 
by calcific deposits in, along, or within one or more elastic lamellae of  the aortic medial layer and is more 
frequently observed than atherosclerotic calcification in patients with CKD (4).
To investigate whether global ATF4 deficiency affects medial calcification, global ATF4-deficient mice 
were generated by backcrossing to DBA/2J mice, which are susceptible to aortic medial calcification (10, 
30). Since ATF4 biallelic KO mice on DBA/2J background are embryonic lethal, we used ATF4-haplo-
deficient (Atf4+/–) mice. DBA/2J Atf4+/– mice and WT (Atf4+/+) mouse littermates were subjected to 5/6 
nephrectomy (nx) to induce CKD. Sham operation was used as normal kidney condition (NKD). Atf4+/– 
mice had approximately 53% lower aortic ATF4 mRNA levels than Atf4+/+ mice (data not shown). 5/6 nx 
increased levels of  serum creatinine and phosphorus, indicators of  CKD (Supplemental Figure 1, A and 
B; supplemental material available online with this article; doi:10.1172/jci.insight.88646DS1). CKD also 
increased serum cholesterol, whereas levels of  serum triglyceride, calcium, and glucose decreased (Supple-
mental Figure 1, C–F). Serum creatinine, phosphorus, cholesterol, triglyceride, calcium, and glucose levels 
were not different between Atf4+/+ and Atf4+/– mice under both NKD and CKD conditions (Supplemental 
Figure 1, A–F).
In the aortic sinus, Atf4+/– mice had 90% and 96% fewer calcified lesions under NKD and CKD condi-
tions, respectively (Figure 1, A and B, and Supplemental Figure 1G). ATF4 haploinsufficiency reduced 
aortic calcium content by 71% under CKD conditions (Figure 1C). VSMC apoptosis and aortic macro-
phage infiltrations are known to contribute to vascular calcification (2, 5, 26, 31–34). Apoptotic cell death, 
as shown by immunofluorescence analysis, TUNEL positivity, and CHOP expression, was significantly 
increased by CKD and reduced by ATF4 haploinsufficiency (Figure 1, D–F). Macrophage infiltrations 
into the aorta were not observed in any of  the groups (data not shown). CKD increased the expression of  
another ER stress marker, KDEL, in the medial layer of  the aorta. ATF4 haploinsufficiency did not alter 
levels of  aortic KDEL protein, suggesting that ER chaperones, such as GRP78 and GRP94, are not major 
targets of  ATF4 in VSMCs (Supplemental Figure 1H).
SMC-specific ATF4 deficiency attenuates medial and atherosclerotic calcification. We next investigated whether 
SMC-specific ATF4 deficiency affects medial calcification. Atf4 conditional floxed (Atf4L/L) and SMMHC-
CreER(T2) mice were backcrossed 10 times to DBA/2J mice. DBA/2J Atf4L/L mice were crossed with DBA/2J 
SMMHC-CreER(T2) mice to generate SMC-Atf4 conditional (SMMHC-CreER(T2); Atf4L/L) mice. DBA/2J SMC-
Atf4 conditional mice were intraperitoneally injected with vehicle or tamoxifen to generate control mice 
and DBA/2J SMC-Atf4 KO mice, respectively. Tamoxifen injection diminished protein expression of  ATF4 
in the aortic medial layers of  SMC-Atf4 KO mice (Figure 2A). These mice were subjected to either sham 
operation or 5/6 nx. CKD, as expected, increased levels of  serum creatinine and phosphorus (Supplemen-
tal Figure 2, A and B), whereas SMC-specific ATF4 deficiency did not affect levels of  serum creatinine, 
phosphorus, calcium, cholesterol, or triglyceride (Supplemental Figure 2, A–E).
CKD induced medial calcification but not atherosclerosis in the aortic sinuses of  DBA/2J mice (Figure 
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2, B and C). SMC-Atf4 KO mice had significantly smaller calcified medial lesions than control mice under 
both NKD and CKD, by 81% and 88%, respectively (Figure 2C and Supplemental Figure 2F). Aortic cal-
cium content was also significantly lower in SMC-Atf4 KO mice under CKD (Figure 2D). mRNA levels of  
ER stress markers such as Atf4 and Chop and osteogenic makers such as alkaline phosphatase, osteopontin, 
and osteocalcin that were upregulated by CKD were attenuated in the medial layer of  aortas of  SMC-Atf4 
KO mice (Supplemental Figure 2G). Consistent with global ATF4 haploinsufficiency, immunofluorescence 
analysis indicated that SMC-specific ATF4 deficiency reduced CKD-induced aortic apoptosis and CHOP 
and ATF4 expression (Figure 2, E and F, and Supplemental Figure 2, H and I).
To study the role of  ATF4 in atherosclerotic calcification, we generated SMC-specific Atf4 KO mice 
on an ApoE-deficient background. Five-week-old SMMHC-CreER(T2); Atf4L/L; ApoE–/– mice were intra-
peritoneally injected with vehicle or tamoxifen to generate control ApoE–/– mice and SMC-specific Atf4 
KO; ApoE–/– mice. Control and SMC-specific Atf4 KO; ApoE–/– mice were subjected to either sham oper-
ation for NKD or 5/6 nx for CKD at 8 weeks of  age. After 12 weeks on a Western diet, control ApoE–/– 
mice under NKD displayed mild atherosclerotic calcification, which was further worsened by CKD. 
However, SMC-specific ATF4 deficiency strongly inhibited vascular calcification under both NKD and 
CKD (Figure 3, A and B). Aortic calcium content was significantly lower in SMC-Atf4 KO mice than in 
control mice under CKD conditions (Figure 3C), supporting the histological analyses. Atherosclerotic 
formation (Figure 3D) and CD68-positive macrophage infiltrations into the aorta (data not shown) 
were not altered by SMC-specific ATF4 deficiency. There were no differences in body weight, serum 
cholesterol, triglyceride, phosphorus, calcium, glucose, and creatinine between control ApoE–/– mice 
Figure 1. ATF4 haploinsufficiency 
attenuates medial calcification. 
(A) Representative photographs 
(original magnification, ×10) of the 
lesions in aortic sinuses stained 
with von Kossa from 8-week-old 
Atf4+/+ and Atf4+/– mice (n = 8–10) 
on DBA/2J background. Mice were 
subjected to either sham opera-
tion for normal kidney condition 
(NKD) or 5/6 nx for chronic kidney 
disease condition (CKD). The mice 
were sacrificed 12 weeks after the 
surgeries. (B) Quantitative analysis 
of calcified lesions in the aortic 
sinus. More NKD data are shown in 
Supplemental Figure 1G. (C) Aortic 
calcium content in Atf4+/– mice. (D) 
Representative micrographs show 
more TUNEL-positive signal (pink) in 
nuclei (blue) of aortic sinus lesions 
from Atf4+/+ mice than from Atf4+/– 
mice. (E) Quantitative analysis of 
TUNEL-positive nuclei (pink) con-
ducted on lesions from Atf4+/– mice. 
(F) Immunofluorescence analysis of 
CHOP (pink) in the aortic sinuses of 
Atf4+/– mice. One-way ANOVA with a 
Student-Newman post-hoc test was 
used for comparison between Atf4+/+ 
and Atf4+/– mice. Two-way ANOVA 
was used for comparison between 
NKD and CKD. **P < 0.01, ***P < 
0.001. Scale bar: 100 μm.
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and SMC-specific Atf4 KO; ApoE–/– mice under both NKD and CKD. As expected, CKD increased 
serum cholesterol, phosphorus, and creatinine in both control and SMC-specific Atf4 KO mice com-
pared with NKD (Supplemental Figure 3).
SMC-specific ATF4 overexpression induces medial and atherosclerotic calcification. We next investigated whether 
CKD-mediated vascular calcification can be mimicked by SMC-specific ATF4 overexpression. The random 
insertion of genetic elements such as a transgene into the mouse genome may lead to the deregulation or 
misregulation of the expression of essential genes. The transgene may also be subject to a variegation or posi-
tion effect. This ultimately leads to biased phenotype observations. To circumvent the random insertion of the 
floxed ATF4 transgene, a conditional human ATF4 transgene was inserted into a permissive locus, Rosa26, by 
the recombinase-mediated cassette exchange procedure that we recently developed (Figure 4A). Conditional 
ATF4 transgenic (TG, Rosa26-ATF4loxtg/+) mice were bred with SMMHC-CreER(T2) mice to generate SMC-ATF4 
conditional transgenic (SMMHC-CreER(T2); Rosa-ATF4loxtg/+) mice. Injection of vehicle or tamoxifen in SMC-
ATF4 conditional transgenic mice caused ATF4 overexpression (Figure 4B). Under NKD, control mice, as 
Figure 2. SMC-specific ATF4 
deficiency attenuates medial 
calcification. (A) Immunoblot 
analysis of ATF4 in the medial 
layer of aortas of control and 
SMC-Atf4 KO mice on DBA/2J 
background. Five-week-old male 
mice were injected with either 
vehicle or 1 mg tamoxifen for 5 
consecutive days. Eight-week-
old control and SMC-Atf4 KO 
mice (n = 8) were subjected to 
either sham operation for normal 
kidney condition (NKD) or 5/6 
nx for chronic kidney disease 
condition (CKD). The mice were 
sacrificed 12 weeks after the 
surgeries. (B) Representative 
photographs (original magni-
fication, ×10) of the lesions in 
aortic sinuses stained with von 
Kossa. Arrows denote calcified 
lesions. (C) Quantitative analysis 
of calcified lesions in the aortic 
sinus. More NKD data are shown 
in Supplemental Figure 2F. 
(D) Aortic calcium content. (E) 
Immunofluorescence analysis of 
CHOP (red) in the aortic media of 
control and SMC-Atf4 KO mice. 
(F) Immunofluorescence-based 
TUNEL analysis of aortic media 
from control and SMC-Atf4 KO 
mice. Representative micro-
graphs show less TUNEL-positive 
signal (pink) in nuclei (blue) of 
lesions from SMC-Atf4 KO mice 
under CKD than from control 
mice. One-way ANOVA with 
a Student-Newman post-hoc 
test was used for comparison 
between control and SMC-Atf4 
KO mice. *P < 0.05, **P < 0.01, 
***P < 0.001. Scale bar: 100 μm.
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expected, did not show mineral deposits in the aortic sinuses, whereas SMC-ATF4 TG mice displayed severe 
medial calcification (Figure 4, C and D). In addition, aortic calcium content was increased by 2.5-fold in SMC-
ATF4 TG mice compared with control mice (Figure 4E). SMC-ATF4 overexpression increased the number of  
apoptotic cells in the aorta (Figure 4, F and G). Serum parameters, including cholesterol, triglyceride, phospho-
rus, and calcium, were not altered by SMC-ATF4 overexpression (Supplemental Figure 4, A–D).
To further investigate whether ATF4 overexpression induces atherosclerotic calcification in addition to 
medial calcification, SMC-ATF4 TG mice were bred with ApoE–/– mice to generate SMMHC-CreER(T2); Rosa-
ATF4loxtg/+; ApoE–/– mice. SMMHC-CreER(T2); Rosa-ATF4loxtg/+; ApoE–/– mice were intraperitoneally injected 
with vehicle or tamoxifen to generate control ApoE–/– mice and SMC-specific ATF4 TG; ApoE–/– mice. 
SMC-ATF4 overexpression did not affect serum cholesterol, triglyceride, phosphorus, or calcium (Supple-
mental Figure 5, A–D) or atherosclerotic lesions (Supplemental Figure 5E). Histological analysis showed 
that SMC-specific ATF4 TG mice displayed severe vascular calcification compared with control ApoE–/– 
mice (Supplemental Figure 5, F and G). In addition, SMC-specific ATF4 overexpression increased aortic 
calcium content by 1.9-fold (Supplemental Figure 5H).
SMC-ATF4 regulates the type III sodium-dependent phosphate cotransporters PiT1 and PiT2. Type III sodium-
dependent phosphate transporters are considered major contributors to vascular calcification (24, 35–37). 
Our previous in vitro studies suggest that ATF4 may regulate vascular calcification through induction of  
phosphate transporter expression (8, 9). To examine this hypothesis, we first analyzed the expression of  
the type III sodium-dependent phosphate transporters SLC20A1 (PiT1) and SLC20A2 (PiT2) in the aortic 
medial layer of  SMC-Atf4 KO and SMC-ATF4 TG mice. Both real-time quantitative PCR and immunoblot 
analysis revealed that ATF4 strongly regulates levels of  both PiT1 and PiT2 expression in the medial layer 
of  aortas. SMC-specific ATF4 deficiency significantly reduced levels of  PiT1 and PiT2 mRNA and protein 
under both NKD and CKD conditions (Figure 5, A and B), whereas SMC-specific ATF4 overexpression 
induced mRNA and protein levels of  both PiT isoforms (Figure 5, C and D). Consistently, VSMCs isolated 
from SMC-Atf4 KO mice had 71% lower phosphate uptake than VSMCs from control mice (Figure 5E). In 
addition, phosphate uptake of  VSMCs increased by 2.7-fold in SMC-ATF4 TG mice (Figure 5F).
Figure 3. SMC-specific ATF4 deficiency 
attenuates atherosclerotic calcification 
but not atherosclerosis. (A) Representa-
tive photographs (original magnification, 
×10) of the lesions in aortic sinuses 
stained with von Kossa. Eight-week-old 
control and SMC-Atf4 KO mice (n = 8) 
on C57Bl/6 ApoE–/– background (control 
ApoE–/– and SMC-Atf4KO; ApoE–/– mice) 
were subjected to either sham opera-
tion for normal kidney condition (NKD) 
or 5/6 nx for chronic kidney condition 
(CKD). The mice were sacrificed 12 weeks 
after the surgeries. Arrows denote calci-
fied lesions. (B) Quantitative analysis 
of calcified lesions in the aortic sinus. 
(C) Aortic calcium content in control 
ApoE–/– and SMC-Atf4KO; ApoE–/– mice 
under NKD and CKD. (D) Quantitative 
analysis of atherosclerotic lesions in the 
aortic sinus. Aortic sinuses were stained 
with Oil Red O. One-way ANOVA with 
a Student-Newman post-hoc test was 
used for statistical analysis. **P < 0.01, 
***P < 0.001. Scale bar: 100 μm.
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The ATF4-C/EBPβ complex regulates transcription of  PiT1 and PiT2 genes. Since ATF4 is a pleiotropic tran-
scription factor, we next proceeded to locate the ATF4 response element (ATF4RE) in the PiT1 gene locus. 
We generated a PiT1 reporter in which the luciferase reporters contained 1.4 kb and 964 bp of  the 5′ flank-
ing region until exon 2 of  the PiT1 gene, allowing the PiT1 gene to drive luciferase expression (Figure 6A). 
The PiT1 reporter construct was cotransfected with CMV-ATF4 into VSMCs. ATF4 expression led to an 
approximately 5.3-fold and 5.8-fold increase in luciferase activity with the –617/+825 and –139/+825 PiT1 
constructs, respectively, but not with the –617/+86 construct. These data suggest that the region between 
positions +86 and +825 contains regulatory sequences that mediate induction by ATF4. To further define 
the regulatory sequences responsible for ATF4 regulation, a homology search was performed using the 
consensus OSE1, cAMP response element (CRE), and ATF-C/EBP response sites, which are known to 
recruit ATF4. Computational analysis of  the PiT1 promoter revealed a putative ATF4RE between posi-
tions +244 and +251 in intron 1 of  the PiT1 gene, showing extensive homology to the ATF-C/EBP site pre-
viously identified in ATF4, VEGF, and CHOP genes (38, 39). To definitively demonstrate that the effect of  
ATF4 on the PiT1 gene is mediated through this putative ATF4RE, point mutations in the ATF4RE were 
generated in the +244 to +251 PiT1 construct and subjected to the same transfection assay. Mutations in the 
ATF4RE of  intron 1 of  PiT1 diminished the response to ATF4 overexpression (Figure 6A). Together, these 
results indicate that an ATF4RE is located in intron 1 of  the PiT1 gene between positions +244 and +251.
Figure 4. SMC-specific ATF4 overexpres-
sion induces medial calcification. (A) 
Scheme of targeting construct design for 
ATF4 transgenic (TG) in the Rosa26 locus. 
Triangles indicate the loxP sites. ATF4 
conditional TG mice were backcrossed 10 
times with DBA/2J mice. ATF4 conditional 
TG mice were crossed with SMMHC-CreER(T2) 
TG mice to generate SMC-ATF4 TG mice. 
Five-week-old male mice under normal 
kidney conditions were injected with 
vehicle or 1 mg tamoxifen for 5 consecu-
tive days to generate control mice and 
SMC-ATF4 TG mice, respectively. The 
mice were sacrificed at 18 weeks of age. 
(B) Immunoblot analysis of ATF4 in the 
medial layer of aortas from control and 
SMC-ATF4 TG mice. (C) Representative 
photographs (original magnification, ×10) 
of the lesions in aortic sinuses stained 
with von Kossa. (D) Quantitative analysis 
of calcified lesions in the aortic sinus. 
(E) Aortic calcium content in control and 
SMC-ATF4 TG mice. (F) Representative 
micrographs (original magnification, ×10) 
show more TUNEL-positive signal (pink) in 
nuclei (blue) of aortic sinus lesions from 
SMC-ATF4 TG mice than from control 
mice. (G) Quantitative analysis of TUNEL-
positive nuclei conducted on aortic sinus 
lesions from SMC-ATF4 TG mice. Two-
tailed unpaired Student’s t test was used 
for statistical analysis. **P < 0.01, ***P < 
0.001. Scale bar: 100 μm.
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To determine whether ATF4 binds 
to the ATF4RE, gel mobility shift assays 
were performed using in vitro–translat-
ed ATF4 proteins and 32P-radiolabeled 
oligonucleotides corresponding to the 
PiT1 ATF4RE (Supplemental Figure 
6A). Double-stranded radiolabeled 
oligonucleotides corresponding to the 
OSE1 of  the osteocalcin promoter 
known to bind with the ATF4 homodi-
mer were used as a control. As expect-
ed, the OSE of  the osteocalcin promoter 
made a shift with the ATF4 recombinant protein, which was blocked by excess WT OSE1 oligonucleotides 
but not the OSE1 mutant. However, the ATF4 protein did not bind to the ATF4RE of  the PiT1 gene 
(Supplemental Figure 6A). These results led us to hypothesize that ATF4 requires another protein as a 
heterodimer partner to bind to the ATF4RE of  the PiT1 gene.
To identify the heterodimer partner of  ATF4 in VSMCs, we performed a yeast 2-hybrid screen using 
the ATF4 bZIP domain as bait and screened against a cDNA library. The library was made using RNA 
from VSMCs treated with stearic acid, which is known to induce ER stress and the subsequent induction of  
ATF4 and vascular calcification. As shown in Supplemental Table 1, we isolated 48 positive clones, which 
included 29 different genes, 4 of  which are known to be transcription factors: C/EBPβ, C/EBPγ, NRF2, 
and Ybx1 (Figure 6B and Supplemental Table 1). We chose C/EBPβ as a candidate for an ATF4 heterodi-
mer partner for the transcriptional regulation of  the PiT1 gene because the yeast 2-hybrid screen suggested 
that C/EBPβ is most abundantly associated with ATF4 in VSMCs (Supplemental Table 1) and because, 
similarly to ATF4, C/EBPβ translation is activated through the phosphorylation of  eIF2α during ER stress 
(40, 41). We therefore investigated whether the ATF4-C/EBPβ complex activates transcription of  the PiT1 
gene. Luciferase assay analysis showed that, while both ATF4 and C/EBPβ independently increased pro-
moter activity of  the PiT1 construct by 3-fold, when both ATF4 and C/EBPβ were coexpressed, the pro-
moter activity was synergistically increased by 10-fold (Figure 6C).
To confirm that ATF4-C/EBPβ heterodimers bind to the ATF4RE of  the PiT1 gene, we performed 
EMSA (Figure 6D). Neither ATF4 nor C/EBPβ recombinant proteins bound alone to the ATF4RE of  the 
PiT1 oligonucleotides, whereas, when both proteins were present, there was a shift in the band of  radio-
labeled oligonucleotides (Figure 6D), indicating binding of  the ATF4-C/EBPβ heterodimer to the PiT1 
WT ATF4RE. The addition of  a 50-fold molar excess of  unlabeled WT PiT1 ATF4RE abolished the shift, 
whereas unlabeled mutant PiT1 ATF4RE oligonucleotides did not (Figure 6D). In addition, C/EBPβ and 
Figure 5. ATF4 regulates the aortic expres-
sion of PiT1 and PiT2. (A) Levels of PiT1 and 
PiT2 mRNA in the medial layer of aortas of 
control and SMC-Atf4 KO mice under normal 
kidney conditions (NKD) and chronic kidney 
disease conditions (CKD). (B) Immunoblot 
analysis of PiT1 and PiT2 in the medial layer 
of aortas of control and SMC-Atf4 KO mice 
under CKD. (C) Levels of PiT1 and PiT2 mRNA 
in the medial layer of aortas of control and 
SMC-ATF4 TG mice. (D) Immunoblot analysis 
of PiT1 and PiT2 in the medial layer of aortas 
of control and SMC-ATF4 TG mice. (E) Inor-
ganic phosphate (Pi) was analyzed in VSMCs 
isolated from the aortas of control and SMC-
Atf4 KO mice. (F) Pi uptake was analyzed in 
VSMCs isolated from the aortas of control 
and SMC-ATF4 TG mice. Two-tailed unpaired 
Student’s t test was used for statistical 
analysis. *P<0.05, **P < 0.01, ***P < 0.001, 
#P<0.05.
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Figure 6. The transcriptional regulation of PiT1 by the ATF4-C/EBPβ complex. (A) Deletion and mutational analysis of the PiT1 gene using a luciferase 
(Luc) reporter gene assay. The schematic illustrations represent the serially deleted PiT/Luc reporter constructs. Results are expressed as the rela-
tive Luc/β-galactosidase units of induction (n-fold) over the control value for each construct. (B) Yeast 2-hybrid screen. Y2HGold yeasts expressing 
ATF4 and/or C/EBPβ were grown onto an SD agar plate placing 4 amino acids (Leu, Trp, Ade, and His) in the presence of X-α-Gal and Aureobasidin A. 
Quadrant 1 of the plate contained a bait vector, pGBKT7-Atf4, and a prey vector, pGADT7-C/ebpβ; quadrant 2 contained a bait vector, pGBKT7-Atf4, 
and a prey vector, pGADT7-Empty; quadrant 3 contained a bait vector, pGBKT7-C/ebpβ, and a prey vector, pGADT7-Empty; and quadrant 4 contained 
a bait vector, pGBKT7-C/ebpβ, and a prey vector, pGADT7-Atf4. (C) The ATF4-C/EBPβ complex induces PiT1 transcription in mammalian cells. NIH 
3T3 cells were cotransfected with pGL3 Luc plasmid containing the –617/+825 PiT1 gene, ATF4-pcDNA3, and/or C/EBPβ-pcDNA3 expression plasmid. 
(D) The ATF4-C/EBPβ complex but not ATF4 or C/EBPβ alone specifically binds to the PiT1 ATF4RE. EMSA was performed using 32P-radiolabeled 
double-stranded oligonucleotides corresponding to the ATF4RE of the PiT1 gene. Competitive assays were performed using a 50-fold molar excess of 
unlabeled oligonucleotides corresponding to the WT ATF4RE or the mutant ATF4 of the PiT1 gene as indicated. Supershift assay was performed using 
C/EBPβ and ATF4 antibody. Black arrow: binding ATF4-C/EBPbeta complex; white arrow: supershift. (E) ATF4 and C/EBPβ belong to the same protein 
complex, which binds to the PiT1 ATF4RE. Double ChIP assays were performed using VSMCs incubated for 6 hours with 500 μM stearic acid that were 
first immunoprecipitated with ATF4 antibody, eluted, and then subjected to a second immunoprecipitation with C/EBPβ antibody or normal rabbit IgG 
antibody. The enrichment of ATF4-C/EBPβ protein was analyzed by real-time quantitative PCR using primer sets specific for the PiT1 ATF4RE or for the 
5′ distal promoter region of PiT1 as a negative control (data not shown). Data were plotted as the percentage of antibody binding versus the amount 
of PCR product obtained using a standardized aliquot of input chromatin (% of input). Two-tailed unpaired Student’s t test was used for statistical 
analysis. *P < 0.05, **P < 0.01, ***P < 0.001.
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ATF4 antibodies produced a supershift of  
the band (Figure 6D), supporting that the 
complex included C/EBPβ.
To further confirm whether ATF4 and 
C/EBPβ bind to the intronic ATF4RE of  
the PiT1 gene, a double ChIP analysis 
was performed in VSMCs that were treat-
ed overnight with 200 μM stearate. The 
isolated chromatin was first immunopre-
cipitated with ATF4 antibody and then 
subjected to a second immunoprecipi-
tation with C/EBPβ antibody or rabbit 
IgG. The double ChIP analysis confirmed 
ATF4-C/EBPβ binding to the region 
(Figure 6E). These results demonstrate 
the specific binding of  the ATF4-C/EBPβ 
complex to the PiT1 ATF4RE. In addition, we also found that the ATF4-C/EBPβ complex activates the 
PiT2 promoter and that the ATF4RE is located in the PiT2 promoter between positions –127 and –111 
(Supplemental Figure 6B).
C/EBPβ regulates mineralization and PiT1 and PiT2 expression in VSMCs. To further confirm the con-
tribution of  C/EBPβ in the regulation of  vascular calcification and phosphate cotransporters, we gener-
ated stable VSMC lines overexpressing C/EBPβ (Figure 7, A and B). As expected, the overexpression 
of  human C/EBPβ induced mineralization of  VSMCs, along with significant increases in inorganic 
phosphate uptake and mRNA and protein levels of  PiT1 and PiT2 (Figure 7, C–F). shRNA-mediated 
inhibition of  C/EBPβ, on the other hand, reduced mineralization, phosphate uptake, and PiT1 and PiT2 
expression (Figure 7, G–L).
In addition, we recently reported that the saturated fatty acid stearic acid strongly induces vascular 
calcification through ER stress (9, 10). We then determined whether saturated fatty acids induce the expres-
sion of  PiT1 and C/EBPβ. Stearic acid treatment increased levels of  PiT1 mRNA and C/EBPβ protein 
(Supplemental Figure 7, A and B) and induced vascular calcification (Supplemental Figure 7C) in control 
VSMCs. We next determined whether PiT1 contributes to stearate-induced vascular calcification. PiT1 
shRNA treatment reduced PiT1 mRNA expression by 74% (Supplemental Figure 7A). PiT1 knockdown 
significantly attenuated stearate-induced vascular calcification (Supplemental Figure 7C).
Figure 7. C/EBPβ regulates mineralization and 
phosphate uptake of VSMCs. Levels of C/EBPβ 
(A) mRNA and (B) protein in VSMCs overex-
pressing C/EBPβ. VSMCs were infected with 
lentiviruses containing human C/EBPβ. A single 
colony was isolated by puromycin selection. (C) 
Mineralization of VSMCs. VSMCs were incubated 
with 2.0 mM phosphate for 7 days. (D) Inorganic 
phosphate (Pi) uptake in VSMCs overexpress-
ing C/EBPβ. Pi uptake was analyzed with 
32P-KH2PO4. Levels of PiT1 and PiT2 (E) mRNA 
and (F) protein in VSMCs overexpressing C/EBPβ. 
Levels of C/EBPβ (G) mRNA and (H) protein in C/
EBPβ knockdown VSMCs. The cells were infected 
with lentiviruses containing C/EBPβ shRNA. A 
single colony was isolated in the presence of 
puromycin. (I) Mineralization of VSMCs. VSMCs 
were incubated with 2.0 mM phosphate for 7 
days. (J) Pi uptake in C/EBPβ knockdown VSMCs. 
Pi uptake was analyzed with 32P-KH2PO4. Levels 
of PiT1 and PiT2 (K) mRNA and (L) protein in C/
EBPβ knockdown VSMCs. *P < 0.05, **P < 0.01, 
***P < 0.001. Two-tailed unpaired Student’s t 
test was used for statistical analysis
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Discussion
ATF4 is known to be a critical transcription factor that regulates skeletal osteogenesis and bone formation 
(19, 20, 42, 43). We and other investigators previously reported that ER stress induces expression of  aortic 
ATF4 in a number of  in vitro and in vivo models of  vascular calcification (1–3, 5, 7–10). In particular, CKD 
strongly activates the aortic ER stress response, resulting in a significant induction of  aortic ATF4 (8). In 
this study, we demonstrate that ATF4 expression in VSMCs plays a causative role in the pathogenesis of  
vascular calcification using a series of  mouse models. As an initial model, we used global ATF4-haploinsuf-
ficient mice, which showed significantly smaller aortic medial calcified lesions under both CKD and NKD 
conditions. We also used an SMC-specific ATF4-deficient model, in which both medial and atherosclerotic 
calcifications under NKD and CKD conditions were attenuated. Finally, we generated a mouse model that 
overexpresses ATF4 only in SMCs, in which severe medial and atherosclerotic calcification developed even 
under NKD. These findings strongly suggest that the ectopic induction of  ATF4 in VSMCs through ER 
stress is a pivotal event in the development of  vascular calcification and osteogenesis.
We also provided mechanistic insights into ATF4-mediated vascular calcification. Our previous in vitro 
studies showed that shRNA-mediated Atf4 knockdown strikingly reduced mRNA levels of  PiT1 and PiT2 
in cultured VSMCs (9, 10). PiT1 and PiT2 are known to contribute to vascular calcification. Consistent 
with our previous in vitro studies, SMC-specific ATF4 deficiency in mice significantly reduced mRNA 
and protein levels of  PiT1 and PiT2 in the medial layer of  aortas, whereas SMC-specific ATF4 overex-
pression induced their levels. Using the promoter deletion assay, we identified ATF4REs in the PiT1 and 
PiT2 genes. The ATF4REs in PiT1 and PiT2 are similar to the ATF-C/EBP site previously identified in a 
number of  genes involved in ER stress, including asparagine synthetase, VEGF, and CHOP genes (38, 39), 
locations where ATF4 binds. EMSA analysis, however, indicated that ATF4 protein alone does not bind to 
the ATF4REs of  the PiT1 and PiT2 genes, although the OSE1 site in the osteocalcin promoter recruits an 
ATF4 homodimer, as previously reported (19, 44). These observations suggest the involvement of  another 
protein in the regulation of  PiT1 and PiT2 genes. Using yeast 2-hybrid screening, EMSA, and double ChIP 
analysis, we indicated that C/EBPβ most abundantly interacts with ATF4 and that the binding is increased 
though the ER stress response in VSMCs. Since the ATF4-C/EBPβ complex is known to promote osteo-
blast differentiation in bone formation, deletion of  either the C/EBPβ or ATF4 gene from mice resulted in 
delayed bone formation, with concurrent suppression of  chondrocyte maturation and osteoblast differenti-
ation. CKD increases ATF4 and C/EBPβ protein levels through ER stress, suggesting that ectopic overpro-
duction of  the ATF4-C/EBPβ complex in VSMCs rather than ATF4 alone leads to vascular calcification 
through the induction of  phosphate uptake. We also demonstrated that C/EBPβ regulates mineralization 
of  VSMCs by altering PiT1 and PiT2 expression, similar to our previous observations on ATF4. Further 
studies will be required to confirm the in vivo contribution of  C/EBPβ and the ATF4-C/EBPβ complex 
in the pathogenesis of  vascular calcification by knocking down and overexpressing C/EBPβ in VSMCs. In 
addition to C/EBPβ, at least 27 other proteins, including C/EBPγ, NRF2, and YBX1, interact with ATF4 
in VSMCs. Further studies will be required to determine whether these proteins are involved in the regula-
tion of  vascular calcification.
CHOP is a major target of  ATF4 (45), and it is a transcription factor that promotes apoptosis con-
tributing to vascular calcification (7, 8). We previously reported that global CHOP deficiency attenuated 
CKD-dependent vascular apoptosis and atherosclerotic calcification in ApoE–/– mice (7). In this study, 
SMC-ATF4 deficiency reduced aortic CHOP expression and CKD-dependent apoptosis accompanied by 
a marked attenuation of  vascular calcification, whereas SMC-ATF4 overexpression induced CHOP expres-
sion and apoptosis. A recent ChIP–seq study showed that the concomitant induction of  ATF4 and CHOP 
makes a complex that mediates ER stress–mediated apoptosis (38, 46). CHOP also strongly interacts with 
C/EBPβ (47, 48). Although our yeast 2-hybrid screen did not find an interaction between ATF4 and CHOP 
in VSMCs, it is still possible that ATF4, CHOP, and C/EBPβ cooperatively mediate CKD-dependent aortic 
apoptosis and vascular calcification. CHOP regulates the expression of  PiT1 but not PiT2 by interacting with 
C/EBPβ, which is mediated through the same DNA element of  PiT1 (+243 to +251) that is regulated by the 
ATF4-C/EBPβ complex (data not shown). In addition, CHOP deficiency reduces aortic PiT1 mRNA and 
protein expression in vivo (7). These results suggest that ATF4 mediates vascular calcification through the 
induction of  phosphate uptake in VSMCs through CHOP-dependent and -independent mechanisms.
In conclusion, using several mouse models, we have demonstrated a pivotal role of  ATF4 in the 
pathogenesis of  vascular calcification in vivo. In addition, our studies revealed that ATF4 regulation of  
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phosphate uptake in VSMCs requires a heterodimer partner, C/EBPβ. Therefore, targeting the ATF4-C/
EBPβ complex and/or its regulating signals in VSMCs may represent a novel therapeutic strategy for 
attenuating vascular calcification.
Methods
Animals. Atf4 conditional KO (lox/lox) mice and SMMHC-CreER(T2) mice were generated as previously 
described (10, 49, 50). SMMHC-Cre/GFP global Atf4+/– and DBA/2J mice were obtained from The Jack-
son Laboratory (51, 52). For SMC-specific ATF4 TG mice, we introduced the transgene at the Rosa26 
locus by the recombinase-mediated cassette exchange method that we recently developed (53) to circum-
vent the inherent problem of  random insertion via traditional pronuclear injection. In brief, we transfect-
ed 5 × 106 R26FNF3-1F1 ES cells with 15 μg of  pFLSLF3-FLAG human ATF4 and 15 μg of  pCAG-Flpe 
(Addgene plasmid 13787). From the 96 clones tested, we found 7 clones with the expected genotype that 
were also G418 sensitive, indicating successful exchange of  the original neo cassette for the transgene 
cassette at the Rosa26 locus. Karyotypically normal ES clones were microinjected into C57BL/6 blasto-
cysts to produce chimeric founders at the University of  Colorado Transgenic Animal Core Facility. The 
generated mice were named Rosa26-ATF4 conditional TG (Rosa26-ATF4loxtg/+) mice. All of  the mouse 
stains were backcrossed more than 10 times with DBA/2J and C57Bl/6J mice. The genetic backgrounds 
were checked at the BioResources Core Facility of  Barbara Davis Center at the University of  Colorado 
Denver. The Atf4lox/lox and Rosa26-ATF4loxtg/+ mice were intercrossed with SMMHC-CreER(T2) mice to obtain 
SMMHC-CreER(T2); Atf4lox/lox mice. Since the SMMHC-CreER(T2) transgene was inserted on the Y chromo-
some, only males were used in this study. Five-week-old males were intraperitoneally injected with either 
1 mg tamoxifen in vegetable oil or vehicle for 5 consecutive days to produce SMC-specific ATF4 KO/
TG mice and control mice, respectively. After the injections, the mice were maintained on a special diet 
(TD10364; Harlan Teklad) for 10 weeks. For VSMC isolation, Atf4lox/lox and Rosa26-ATF4loxtg/+ mice were 
intercrossed with constitutively active SMMHC-Cre/GFP mice. CKD was induced using 5/6 nx as previ-
ously reported, whereas sham operation was used as an NKD condition (7, 8, 54).
Cell cultures. Murine aortic VSMCs (passages 6–10) were isolated from the aortas of  control, SMC-
Atf4 KO, and SMC-ATF4 TG mice as described previously (55, 56). Cells were maintained in DMEM 
containing 10% FBS. Mouse VSMCs (MOVAS-1, ATCC) were infected with recombinant lentivi-
ruses containing C/ebpβ shRNA (clone TRCN0000007442, Open Biosystems), PiT1 shRNA (clone 
V2LMM_33774, Open Biosystems), and human C/EBPβ cDNA (Thermo Fisher). Colonies were select-
ed by treatment with 5 μg/ml puromycin or blasticidin, respectively, for 7 days.
Histological analysis. Calcified lesions in the aortic sinus were analyzed as previously described (7, 10, 
54). To distinguish between calcified lesions and pigments on the aortic valve leaflets, histological images 
were captured before and after von Kossa staining. Apoptotic cells and CHOP in the medial layer of  aortic 
sinuses were detected using an In Situ Cell Death Detection Kit (Roche), a CD68 monoclonal antibody 
(FA-11, AbD Serotec), an α-smooth muscle actin antibody (1A4, Sigma-Aldrich), an ATF4 monoclonal 
antibody (D4B8, Cell Signaling Technology), and a CHOP monoclonal antibody (L63F7, Cell Signaling 
Technology) as previously described (7, 8, 57). At least 5 sections from each sample were analyzed.
Immunoblot analysis. Cell and tissue lysates were prepared using RIPA buffer (Cell Signaling). The sam-
ples were separated by SDS-PAGE, transferred to a nitrocellulose membrane, and immunoblotted with the 
following antibodies: ATF4 (D4B8) from Cell Signaling and PiT1 (H-130), PiT2 (B-4), C/EBPβ (C-19), 
and GAPDH (V-18) from Santa Cruz Biotechnology. Samples were visualized using horseradish peroxi-
dase coupled to appropriate secondary antibodies, with enhancement by an ECL detection kit (Thermo 
Fisher Scientific).
Calcium content in cultured cells and aortas. Calcium deposition in cultured cells and aortas was quantified 
as previously described (7–10, 54).
Inorganic phosphate uptake measurement. Sodium-dependent uptake of  phosphate was measured in 
VSMCs grown to confluency on 12-well plastic dishes as previously described (8, 9).
RNA analysis. Real-time quantitative PCR assays were performed using an Applied Biosystems StepOne 
qPCR instrument. Quantitative expression values were calculated from an absolute standard curve method 
using the plasmid template (Open Biosystems) containing each target gene cDNA. Primer sequences that 
are fully validated were obtained from the Primer Bank (Harvard University, https://pga.mgh.harvard.
edu/primerbank/) and published previously (10).
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Yeast 2-hybrid screen. Matchmaker library construction and screen kits were purchased from Clontech. 
A VSMC library was generated and the screen was performed as described in the manufacturer’s protocols, 
using total RNA from VSMCs treated with 200 μM stearic acid for 16 hours. Atf4 cDNA was subcloned 
into the pGBKT7 bait vector. Procedures for culture media, plates for yeast growth, and selection were fol-
lowed as described in the manufacturer’s protocols. Positive clones were sequenced and identified using the 
BLAST search on the UCSC Genome Bioinformatics (http://genome.ucsc.edu/).
Transfections and luciferase assays. NIH 3T3 cells (ATCC) were grown at 37°C in an atmosphere of  5% 
CO2 in DMEM containing 25 mM glucose, 100 U/ml penicillin, and 100 μg/ml streptomycin and supple-
mented with 10% fetal bovine serum. Transient transfections of  NIH 3T3 cells were performed in triplicate 
in 24-well plates. Cells were transfected with 200 ng of  firefly luciferase reporter plasmids (pGL3, Prome-
ga), 50 ng of  expression plasmids, and 100 ng of  pCMV-LacZ vector using Turbofect transfection reagent 
(Fisher). Six hours after transfection, cells were incubated in DMEM containing 10% fetal bovine serum. 
Luciferase activities were measured using a luciferase assay system (Promega). Firefly luciferase activity 
was divided by β-galactosidase activity to obtain a normalized value, the relative luciferase unit. Expression 
plasmids for human ATF4 (plasmid 26114) and C/EBPβ (plasmid 12558) were purchased from Addgene.
In vitro transcription/translation and EMSA. Human ATF4 and C/EBPβ proteins were synthesized in 
vitro from pGEM-ATF4 and pGEM-C/EBPβ using the TNT quick-coupled transcription/translation sys-
tem (Promega) as previously described (58). Double-stranded oligonucleotides corresponding to the ATF4 
RE of  the PiT1 gene (PiT1 WT ATF4RE, 5′-GCGGCACCGGTGGTGCAAAGGTCCTTTCT-3′) and the 
OSE of  the osteocalcin promoter (5′-CTCCCCTGCTCCTCCTGCTTACATCAGAGAGCACA-3′) were 
32P radiolabeled with polynucleotide kinase. Protein-DNA–binding assays were performed by incubating 
the protein and radiolabeled probes at room temperature for 20 minutes, followed by 15 minutes on ice. 
Salmon sperm DNA was added into the binding assays to reduce nonspecific binding of  labeled oligo-
nucleotides. A 50-fold molar excess of  unlabeled double-stranded mutant PiT1 ATF4RE gene (PiT1 Mut 
ATF4RE, 5′-GCGGCACCGGTGGGGCGTAGGTCCTTTCT-3′) or unlabeled double-stranded mutant 
OSE1 of  the osteocalcin promoter (Mut OSE1, 5′-CTCCCCTGCTCTTGGAGCATGCATCAGAGAG-
CACA-3′) was used for the competition experiments. The underlines denote nucleotide mutations. The 
DNA-protein complexes were resolved on a 5% polyacrylamide gel in 1 M Tris-borate-EDTA buffer. The 
gels were dried and autoradiographed at –80°C.
Double ChIP analysis. ChIP was performed using an ATF4 antibody that was incubated for 30 minutes 
at 37°C in elution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 
mM NaCl, 10mM DTT). The supernatant was diluted 100-fold with ChIP dilution buffer (25 mM Tris-HCl, 
pH 8.0, 2 mM EDTA, 150 mM NaCl, 1% Triton X-100) and then subjected to a second immunoprecipita-
tion using either C/EBPβ antibody or normal rabbit IgG antibody. Purified immunoprecipitated DNA was 
analyzed by real-time quantitative PCR. The results are expressed as the percentage of  antibody binding 
versus the amount of  PCR product obtained using a standardized aliquot of  input chromatin (% of  input). 
The primers for the PiT1 gene are as follows: sense, 5′-TGCTTCACGAGTGGGTAGAG-3′, and antisense, 
5′-GCCCACTCCAGAGAAGAAAG-3′. The following primers were used as a negative control: sense, 
5′-GGAGAAAGCACTTGAGAGGAATA-3′, and antisense, 5′-GCAGTCAGAGGAATGAGTGTAG-3′.
Biochemical analysis. Serum cholesterol, triglyceride, phosphorus, and calcium were analyzed using col-
orimetric enzyme assay kits (Pointe Scientific, cholesterol C7510; triglyceride T7532; phosphorus P7516; 
calcium C7503). Serum creatinine was analyzed with LC-MS/MS as previously described (7, 10).
Statistics. Data were collected from more than 2 independent experiments and are reported as mean 
± SEM. Statistical analysis was performed using a 2-tailed Student’s t test for 2-group comparisons and 
a 1-way ANOVA with a Student-Newman post-hoc test or a 2-way ANOVA for multigroup comparison. 
Significance was accepted at P < 0.05.
Study approval. All animal protocols and experimental procedures were approved by the Institutional 
Animal Care and Use Committees at the University of  Colorado Denver.
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